The drug, lecanemab, made by Eisai and Biogen, also carried risks of brain swelling and bleeding and should be studied further, a report of the findings said.
Author: PAM BELLUCK
Advertisements
{
"slotId": "6845006044",
"unitType": "responsive",
"resize": "auto"
}